Probiotics for the treatment or prevention of atopic dermatitis: A review of the evidence from randomized controlled trials

American Journal of Clinical Dermatology

Volumn 9, Issue 2, 2008, Pages 93-103

  Betsi, Gregoria I ^a,b   Papadavid, Evangelia ^c   Falagas, Matthew E ^a,d,e,f  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b General Hospital of Sparta   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HENRY DUNANT HOSPITAL   (Greece)

^f NONE   (Greece)

Author keywords

Atopic dermatitis, prevention; Atopic dermatitis, treatment; Probiotics, therapeutic use

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; GALACTOSE OLIGOSACCHARIDE; GAMMA INTERFERON; INTERLEUKIN 4; PLACEBO; PROBIOTIC AGENT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ATOPIC DERMATITIS; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BREVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LABORATORY TEST; LACTOBACILLUS FERMENTUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; PROPIONIBACTERIUM FREUDENREICHII; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; BIFIDOBACTERIUM; BIOLOGICAL MARKERS; CHILD; CYTOKINES; DERMATITIS, ATOPIC; FEMALE; HUMANS; INFANT; LACTOBACILLUS; PREGNANCY; PROBIOTICS; PROPIONIBACTERIUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 39549097953     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200809020-00002     Document Type: Review

References (63)

1. Williams HC. Atopic dermatitis. N Engl J Med 2005; 352: 2314-24
2. Reid G, Jass J, Sebulsky T, et al. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003; 16: 658-72
3. Bjorksten B, Sepp E, Julge K, et al. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001; 108 (4): 516-20
4. Bongaerts GPA, Severijnen RSVM. Preventive and curative effects of probiotics in atopic patients. Med Hypotheses 2005; 64: 1089-92
5. Isolauri E, Sutas Y, Kankaanpaa P, et al. Probiotics: effects on immunity. Am J Clin Nutr 2001; 73: 444-50
6. Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997; 99 (2): 179-85
7. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr 2003; 36: 223-7
8. Isolauri E, Arvola T, Sutas Y, et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30 (11): 1604-10
9. Weston S, Halbert A, Richmond P, et al. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child 2005 Sep; 90 (9): 892-7
10. Viljanen M, Savilahti E, Haahtela T, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005; 60 (4): 494-500
11. Rosenfeldt V, Benfeldt E, Nielsen SD, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003; 111: 389-95
12. Sistek D, Kelly R, Wickens K, et al. Is the effect of probiotics on atopic dermatitis confined to food sensitized children? Clin Exp Allergy 2006; 36 (5): 629-33
13. Brouwer ML, Wolt-Plompen SA, Dubois AE, et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exp Allergy 2006 Jul; 36 (7): 899-906
14. Folster-Holst R, Muller F, Schnopp N, et al. Prospective, randomised controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol 2006; 155: 1256-61
15. Pohjavuori E, Viljanen M, Korpela R, et al. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. J Allergy Clin Immunol 2004; 114: 131-6
16. Prescott SL, Dunstan JA, Hale J, et al. Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. Clin Exp Allergy 2005 Dec; 35 (12): 1557-64
17. Viljanen M, Kuitunen M, Haahtela T, et al. Probiotic effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants. Pediatr Allergy Immunol 2005; 16: 65-71
18. Rosenfeldt V, Benfeldt E, Valerius NH, et al. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr 2004; 145: 612-6
19. Kankaanpaa PE, Yang B, Kallio HP, et al. Influence of probiotic supplemented infant formula on composition of plasma lipids in atopic infants. J Nutr Biochem 2002; 13 (6): 364-9
20. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002; 109 (1): 119-21
21. Kalliomaki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357 (9262): 1076-9
22. Kukkonen K, Savilahti E, Haahtela T, et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomised, doubleblind, placebo-controlled trial. J Allergy Clin Immunol 2007; 119: 192-8
23. Taylor A, Dunstan J, Prescott S. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitisation in high-risk children: a randomised controlled trial. J Allergy Clin Immunol 2007; 119: 184-91
24. Viljanen M, Pohjavuori E, Haahtela T, et al. Induction of inflammation as a possible mechanism of probiotic effect in atopic eczema-dermatitis syndrome. J Allergy Clin Immunol 2005; 115 (6): 1254-9
25. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; 92: 44-7
26. Williams HC, Burney PG, Pembroke AC, et al. The U.K. Working Party's diagnostic criteria for atopic dermatitis: III. Independent hospital validation. Br J Dermatol 1994; 131: 406-16
27. Williams HC. Two positive studies of probiotics for atopic dermatitis. Arch Dermatol 2006; 142: 1201-3
28. Kawamoto N, Kaneko H, Takemura M, et al. Age-related changes in intracellular cytokine profiles and Th2 dominance in allergic children. Pediatr Allergy Immunol 2006; 17 (2): 125-33
29. Kallstrom E, Roscher I, Andreasson A, et al. Decreased frequency of intracellular IFN-gamma producing T cells in whole blood preparations from patients with atopic dermatitis. Exp Dermatol 2002; 11 (6): 556-63
30. Tang M, Kemp A, Varigos G. IL-4 and interferon-gamma production in children with atopic disease. Clin Exp Immunol 1993; 92 (1): 120-4
31. Dunstan JA, Hale J, Breckler L, et al. Atopic dermatitis in young children is associated with impaired interleukin-10 and interferon-gamma responses to allergens, vaccines and colonizing skin and gut bacteria. Clin Exp Allergy 2005; 35 (10): 1309-17
32. Machura E, Mazur B, Kwiecien J, et al. Intracellular production of IL-2, IL-4, IFN-gamma, and TNF-alpha by peripheral blood CD3+ and CD4+ T cells in children with atopic dermatitis. Eur J Pediatr 2007; 166 (8): 789-95
33. Sutas Y, Soppi E, Korhonen H, et al. Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus casei GG-derived enzymes. J Allergy Clin Immunol 1996; 98 (1): 216-24
34. Sutas Y, Hurme M, Isolauri E. Down-regulation of anti-CD3 antibody-induced IL-4 production by bovine caseins hydrolysed with Lactobacillus GG-derived enzymes. Scand J Immunol 1996; 43 (6): 687-9
35. Miettinen M, Vuopio-Varkila J, Varkila K. Production of human tumor necrosis factor alpha, interleukin-6 and interleukin-10 is induced by lactic acid bacteria. Infect Immun 1996; 64: 5403-5
36. Poulsen LK, Bindslev-Jensen C, Diamant M, et al. Biomolecular regulation of the IgE immune response: III. Cytokine profiles in atopic dermatitis, inhalant allergy and non-allergic donors. Cytokine 1996; 8 (8): 651-7
37. Takahashi T, Sasaki Y, Hama K, et al. Production of IL-4, IL-2, IFN-gamma, and TNF-alpha by peripheral blood mononuclear cells of patients with atopic dermatitis. J Dermatol Sci 1992; 3 (3): 172-80
38. Antunez C, Torres MJ, Mayorga C, et al. Different cytokine production and activation marker profiles in circulating cutaneous-lymphocyte-associated antigen T cells from patients with acute or chronic atopic dermatitis. Clin Exp Allergy 2004; 34 (4): 559-66
39. Reinhold U, Pawelec G, Wehrmann W, et al. Cytokine release from cultured peripheral blood mononuclear cells of patients with severe atopic dermatitis. Acta Derm Venereol 1989; 69 (6): 497-502
40. Seneviratne SL, Jones L, Bailey AS, et al. Severe atopic dermatitis is associated with a reduced frequency of IL-10 producing allergen-specific CD4+ T cells. Clin Exp Dermatol 2006; 31 (5): 689-94
41. Pellegrino M, Minervini B, Musto P, et al. Tumor necrosis factor-alpha and interleukin-1 beta: two possible mediators of allergic inflammation. Minerva Pediatr 1996; 48 (7-8): 309-12
42. Sumimoto S, Kawai M, Kasajima Y, et al. Increased plasma tumour necrosis factor-alpha concentration in atopic dermatitis. Arch Dis Child 1992; 67 (3): 277-9
43. de Vries IJ, Langeveld-Wildschut EG, van Reijsen FC, et al. Adhesion molecule expression on skin endothelia in atopic dermatitis: effects of TNF-alpha and IL-4. J Allergy Clin Immunol 1998; 102 (3): 461-8
44. Noso N, Sticherling M, Bartels J, et al. Identification of an N-terminally truncated form of the chemokine RANTES and granulocyte-macrophage colony-stimulating factor as major eosinophil attractants released by cytokine-stimulated dermal fibroblasts. J Immunol 1996; 156 (5): 1946-53
45. Yamada H, Matsukura M, Yudate T, et al. Enhanced production of RANTES, an eosinophil chemoattractant factor, by cytokine-stimulated epidermal keratino-cytes. Int Arch Allergy Immunol 1997; 114 Suppl. 1: 28-32
46. Angelova-Fischer I, Hipler UC, Bauer A, et al. Significance of interleukin-16, macrophage-derived chemokine, eosinophil cationic protein and soluble E-selectin in reflecting disease activity of atopic dermatitis: from laboratory parameters to clinical scores. Br J Dermatol 2006; 154 (6): 1112-7
47. Pucci N, Lombardi E, Novembre E, et al. Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: correlation with disease activity. J Allergy Clin Immunol 2000; 105 (2 Pt 1): 353-7
48. Gebhardt M, Wenzel HC, Hipler UC, et al. Monitoring of serologic immune parameters in inflammatory skin diseases. Allergy 1997; 52 (11): 1087-94
49. Miyasato M, Tsuda S, Nakama T, et al. Serum levels of eosinophil cationic protein reflect the state of in vitro degranulation of blood hypodense eosinophils in atopic dermatitis. J Dermatol 1996; 23 (6): 382-8
50. Nakama T. Relationships between eosinophil-associated parameters and disease severity in atopic dermatitis. Kurume Med J 1995; 42 (2): 95-106
51. Kristjansson S, Shimizu T, Strannegard IL, et al. Eosinophil cationic protein, myeloperoxidase and tryptase in children with asthma and atopic dermatitis. Pediatr Allergy Immunol 1994; 5 (4): 223-9
52. Czech W, Krutmann J, Schopf E, et al. Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis. Br J Dermatol 1992; 126 (4): 351-5
53. Sugai T, Sakiyama Y, Matumoto S. Eosinophil cationic protein in peripheral blood of pediatric patients with allergic diseases. Clin Exp Allergy 1992; 22 (2): 275-81
54. Paganelli R, Fanales-Belasio E, Carmini D, et al. Serum eosinophil cationic protein in patients with atopic dermatitis. Int Arch Allergy Appl Immunol 1991; 96 (2): 175-8
55. Majamaa H, Laine S, Miettinen A. Eosinophil protein X and eosinophil cationic protein as indicators of intestinal inflammation in infants with atopic eczema and food allergy. Clin Exp Allergy 1999; 29 (11): 1502-6
56. Tsuda S, Kato K, Miyasato M, et al. Eosinophil involvement in atopic dermatitis as reflected by elevated serum levels of eosinophil cationic protein. J Dermatol 1992; 19 (4): 208-13
57. Slobodna MS, Jasna L, Vesna Z, et al. Serum eosinophil cationic protein in children with atopic dermatitis. Int J Dermatol 2006; 45 (10): 1156-60
58. Wolkerstorfer A, Laan MP, Savelkoul HF, et al. Soluble E-selectin, other markers of inflammation and disease severity in children with atopic dermatitis. Br J Dermatol 1998; 138 (3): 431-5
59. Arkwright PD, Chase JM, Babbage S, et al. Atopic dermatitis is associated with a low-producer transforming growth factor beta(1) cytokine genotype. J Allergy Clin Immunol 2001; 108 (2): 281-4
60. Lee HJ, Lee HP, Ha SJ, et al. Spontaneous expression of mRNA for IL-10, GM-CSF, TGF-beta, TGF-alpha, and IL-6 in peripheral blood mononuclear cells from atopic dermatitis. Ann Allergy Asthma Immunol 2000; 84 (5): 553-8
61. Laiho K, Lampi AM, Hamalainen M, et al. Breast milk fatty acids, eicosanoids, and cytokines in mothers with and without allergic disease. Pediatr Res 2003; 53 (4): 642-7
62. Nowak-Wegrzyn A. Future approaches to food allergy. Pediatrics 2003; 111: 1672-80
63. Matricardi PM, Bjorksten B, Bonini S, et al. Microbial products in allergy prevention and therapy. Allergy 2003; 58: 461-71